Selected research
Market Structure
Global Vaccine (Include COVID-19) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Vaccine (Include COVID-19) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Vaccine (Include COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Vaccine (Include COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Vaccine (Include COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Vaccine (Include COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Vaccine (Include COVID-19) include Sanofi, Merck, Pfizer, GSK, AstraZeneca, Zhejiang Pukang, Walvax Biotechnology, Viatris and Sinovac, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Vaccine (Include COVID-19) market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Vaccine (Include COVID-19) and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Vaccine (Include COVID-19) revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Vaccine (Include COVID-19) market size, projected growth trends, production technologies, key applications, and end-use industries.
Vaccine (Include COVID-19) Segment by Company
Sanofi
Merck
Pfizer
GSK
AstraZeneca
Zhejiang Pukang
Walvax Biotechnology
Viatris
Sinovac
Sinovac
Serum Institute
Panacea Biotec Ltd
LG Life Sciences
KM Biologics
Hualan Bio
Halfkin Bio-Pharmaceuticals
CSL
Changchun Institute of Biological
Bio-Med
Bharat Biotech
Vaccine (Include COVID-19) Segment by Type
Inactivated Vaccine
Attenuated Vaccine
mRNA
Other
Vaccine (Include COVID-19) Segment by Application
Public
Private
Vaccine (Include COVID-19) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine (Include COVID-19) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vaccine (Include COVID-19) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine (Include COVID-19).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Vaccine (Include COVID-19) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vaccine (Include COVID-19) industry.
Chapter 3: Detailed analysis of Vaccine (Include COVID-19) companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vaccine (Include COVID-19)revenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Inactivated Vaccine
- Attenuated Vaccine
- mRNA
- Other
Applications
- Public
- Private
Companies covered
- Sanofi
- Merck
- Pfizer
- GSK
- AstraZeneca
- Zhejiang Pukang
- Walvax Biotechnology
- Viatris
- Sinovac
- Sinovac
- Serum Institute
- Panacea Biotec Ltd
- LG Life Sciences
- KM Biologics
- Hualan Bio
- Halfkin Bio-Pharmaceuticals
- CSL
- Changchun Institute of Biological
- Bio-Med
- Bharat Biotech
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Vaccine (Include COVID-19) Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Inactivated Vaccine
- 1.2.3 Attenuated Vaccine
- 1.2.4 mRNA
- 1.2.5 Other
- 1.3 Market Analysis by Application
- 1.3.1 Global Vaccine (Include COVID-19) Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Public
- 1.3.3 Private
- 1.4 Global Market Growth Prospects
- 1.5 Global Vaccine (Include COVID-19) Growth Trends by Region
- 1.5.1 Global Vaccine (Include COVID-19) Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Vaccine (Include COVID-19) Market Size by Region (2021-2026)
- 1.5.3 Vaccine (Include COVID-19) Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Vaccine (Include COVID-19) Market Dynamics
- 2.1 Vaccine (Include COVID-19) Industry Trends
- 2.2 Vaccine (Include COVID-19) Industry Drivers
- 2.3 Vaccine (Include COVID-19) Industry Opportunities and Challenges
- 2.4 Vaccine (Include COVID-19) Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Vaccine (Include COVID-19) Revenue by Company (2021-2026)
- 3.2 Global Vaccine (Include COVID-19) Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Vaccine (Include COVID-19) Key Company Head office and Area Served
- 3.4 Global Vaccine (Include COVID-19) Company, Product Type & Application
- 3.5 Global Vaccine (Include COVID-19) Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Vaccine (Include COVID-19) Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Vaccine (Include COVID-19) Players Market Share by Revenue in 2025
- 3.6.3 2025 Vaccine (Include COVID-19) Tier 1, Tier 2, and Tier 3
4 Vaccine (Include COVID-19) Market by Type
- 4.1 Global Vaccine (Include COVID-19) Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Vaccine (Include COVID-19) Market Size by Type (2021-2032)
- 4.3 Global Vaccine (Include COVID-19) Market Size Share by Type (2021-2032)
5 Vaccine (Include COVID-19) Market by Application
- 5.1 Global Vaccine (Include COVID-19) Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Vaccine (Include COVID-19) Market Size by Application (2021-2032)
- 5.3 Global Vaccine (Include COVID-19) Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Sanofi
- 6.1.1 Sanofi Company Information
- 6.1.2 Sanofi Business Overview
- 6.1.3 Sanofi Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Sanofi Vaccine (Include COVID-19) Product Portfolio
- 6.1.5 Sanofi Recent Developments
- 6.2 Merck
- 6.2.1 Merck Company Information
- 6.2.2 Merck Business Overview
- 6.2.3 Merck Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Merck Vaccine (Include COVID-19) Product Portfolio
- 6.2.5 Merck Recent Developments
- 6.3 Pfizer
- 6.3.1 Pfizer Company Information
- 6.3.2 Pfizer Business Overview
- 6.3.3 Pfizer Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Pfizer Vaccine (Include COVID-19) Product Portfolio
- 6.3.5 Pfizer Recent Developments
- 6.4 GSK
- 6.4.1 GSK Company Information
- 6.4.2 GSK Business Overview
- 6.4.3 GSK Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 GSK Vaccine (Include COVID-19) Product Portfolio
- 6.4.5 GSK Recent Developments
- 6.5 AstraZeneca
- 6.5.1 AstraZeneca Company Information
- 6.5.2 AstraZeneca Business Overview
- 6.5.3 AstraZeneca Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 AstraZeneca Vaccine (Include COVID-19) Product Portfolio
- 6.5.5 AstraZeneca Recent Developments
- 6.6 Zhejiang Pukang
- 6.6.1 Zhejiang Pukang Company Information
- 6.6.2 Zhejiang Pukang Business Overview
- 6.6.3 Zhejiang Pukang Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Zhejiang Pukang Vaccine (Include COVID-19) Product Portfolio
- 6.6.5 Zhejiang Pukang Recent Developments
- 6.7 Walvax Biotechnology
- 6.7.1 Walvax Biotechnology Company Information
- 6.7.2 Walvax Biotechnology Business Overview
- 6.7.3 Walvax Biotechnology Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Walvax Biotechnology Vaccine (Include COVID-19) Product Portfolio
- 6.7.5 Walvax Biotechnology Recent Developments
- 6.8 Viatris
- 6.8.1 Viatris Company Information
- 6.8.2 Viatris Business Overview
- 6.8.3 Viatris Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Viatris Vaccine (Include COVID-19) Product Portfolio
- 6.8.5 Viatris Recent Developments
- 6.9 Sinovac
- 6.9.1 Sinovac Company Information
- 6.9.2 Sinovac Business Overview
- 6.9.3 Sinovac Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Sinovac Vaccine (Include COVID-19) Product Portfolio
- 6.9.5 Sinovac Recent Developments
- 6.10 Sinovac
- 6.10.1 Sinovac Company Information
- 6.10.2 Sinovac Business Overview
- 6.10.3 Sinovac Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Sinovac Vaccine (Include COVID-19) Product Portfolio
- 6.10.5 Sinovac Recent Developments
- 6.11 Serum Institute
- 6.11.1 Serum Institute Company Information
- 6.11.2 Serum Institute Business Overview
- 6.11.3 Serum Institute Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Serum Institute Vaccine (Include COVID-19) Product Portfolio
- 6.11.5 Serum Institute Recent Developments
- 6.12 Panacea Biotec Ltd
- 6.12.1 Panacea Biotec Ltd Company Information
- 6.12.2 Panacea Biotec Ltd Business Overview
- 6.12.3 Panacea Biotec Ltd Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Panacea Biotec Ltd Vaccine (Include COVID-19) Product Portfolio
- 6.12.5 Panacea Biotec Ltd Recent Developments
- 6.13 LG Life Sciences
- 6.13.1 LG Life Sciences Company Information
- 6.13.2 LG Life Sciences Business Overview
- 6.13.3 LG Life Sciences Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 LG Life Sciences Vaccine (Include COVID-19) Product Portfolio
- 6.13.5 LG Life Sciences Recent Developments
- 6.14 KM Biologics
- 6.14.1 KM Biologics Company Information
- 6.14.2 KM Biologics Business Overview
- 6.14.3 KM Biologics Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 KM Biologics Vaccine (Include COVID-19) Product Portfolio
- 6.14.5 KM Biologics Recent Developments
- 6.15 Hualan Bio
- 6.15.1 Hualan Bio Company Information
- 6.15.2 Hualan Bio Business Overview
- 6.15.3 Hualan Bio Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Hualan Bio Vaccine (Include COVID-19) Product Portfolio
- 6.15.5 Hualan Bio Recent Developments
- 6.16 Halfkin Bio-Pharmaceuticals
- 6.16.1 Halfkin Bio-Pharmaceuticals Company Information
- 6.16.2 Halfkin Bio-Pharmaceuticals Business Overview
- 6.16.3 Halfkin Bio-Pharmaceuticals Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Halfkin Bio-Pharmaceuticals Vaccine (Include COVID-19) Product Portfolio
- 6.16.5 Halfkin Bio-Pharmaceuticals Recent Developments
- 6.17 CSL
- 6.17.1 CSL Company Information
- 6.17.2 CSL Business Overview
- 6.17.3 CSL Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.17.4 CSL Vaccine (Include COVID-19) Product Portfolio
- 6.17.5 CSL Recent Developments
- 6.18 Changchun Institute of Biological
- 6.18.1 Changchun Institute of Biological Company Information
- 6.18.2 Changchun Institute of Biological Business Overview
- 6.18.3 Changchun Institute of Biological Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.18.4 Changchun Institute of Biological Vaccine (Include COVID-19) Product Portfolio
- 6.18.5 Changchun Institute of Biological Recent Developments
- 6.19 Bio-Med
- 6.19.1 Bio-Med Company Information
- 6.19.2 Bio-Med Business Overview
- 6.19.3 Bio-Med Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.19.4 Bio-Med Vaccine (Include COVID-19) Product Portfolio
- 6.19.5 Bio-Med Recent Developments
- 6.20 Bharat Biotech
- 6.20.1 Bharat Biotech Company Information
- 6.20.2 Bharat Biotech Business Overview
- 6.20.3 Bharat Biotech Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.20.4 Bharat Biotech Vaccine (Include COVID-19) Product Portfolio
- 6.20.5 Bharat Biotech Recent Developments
7 North America
- 7.1 North America Vaccine (Include COVID-19) Market Size (2021-2032)
- 7.2 North America Vaccine (Include COVID-19) Market Size by Type
- 7.2.1 North America Vaccine (Include COVID-19) Market Size by Type (2021-2026)
- 7.2.2 North America Vaccine (Include COVID-19) Market Size by Type (2027-2032)
- 7.2.3 North America Vaccine (Include COVID-19) Market Share by Type (2021-2032)
- 7.3 North America Vaccine (Include COVID-19) Market Size by Application
- 7.3.1 North America Vaccine (Include COVID-19) Market Size by Application (2021-2026)
- 7.3.2 North America Vaccine (Include COVID-19) Market Size by Application (2027-2032)
- 7.3.3 North America Vaccine (Include COVID-19) Market Share by Application (2021-2032)
- 7.4 North America Vaccine (Include COVID-19) Market Size by Country
- 7.4.1 North America Vaccine (Include COVID-19) Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Vaccine (Include COVID-19) Market Size by Country (2021-2026)
- 7.4.3 North America Vaccine (Include COVID-19) Market Size by Country (2027-2032)
- 7.4.4 North America Vaccine (Include COVID-19) Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Vaccine (Include COVID-19) Market Size (2021-2032)
- 8.2 Europe Vaccine (Include COVID-19) Market Size by Type
- 8.2.1 Europe Vaccine (Include COVID-19) Market Size by Type (2021-2026)
- 8.2.2 Europe Vaccine (Include COVID-19) Market Size by Type (2027-2032)
- 8.2.3 Europe Vaccine (Include COVID-19) Market Share by Type (2021-2032)
- 8.3 Europe Vaccine (Include COVID-19) Market Size by Application
- 8.3.1 Europe Vaccine (Include COVID-19) Market Size by Application (2021-2026)
- 8.3.2 Europe Vaccine (Include COVID-19) Market Size by Application (2027-2032)
- 8.3.3 Europe Vaccine (Include COVID-19) Market Share by Application (2021-2032)
- 8.4 Europe Vaccine (Include COVID-19) Market Size by Country
- 8.4.1 Europe Vaccine (Include COVID-19) Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Vaccine (Include COVID-19) Market Size by Country (2021-2026)
- 8.4.3 Europe Vaccine (Include COVID-19) Market Size by Country (2027-2032)
- 8.4.4 Europe Vaccine (Include COVID-19) Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Vaccine (Include COVID-19) Market Size (2021-2032)
- 9.2 China Vaccine (Include COVID-19) Market Size by Type
- 9.2.1 China Vaccine (Include COVID-19) Market Size by Type (2021-2026)
- 9.2.2 China Vaccine (Include COVID-19) Market Size by Type (2027-2032)
- 9.2.3 China Vaccine (Include COVID-19) Market Share by Type (2021-2032)
- 9.3 China Vaccine (Include COVID-19) Market Size by Application
- 9.3.1 China Vaccine (Include COVID-19) Market Size by Application (2021-2026)
- 9.3.2 China Vaccine (Include COVID-19) Market Size by Application (2027-2032)
- 9.3.3 China Vaccine (Include COVID-19) Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Vaccine (Include COVID-19) Market Size (2021-2032)
- 10.2 Asia Vaccine (Include COVID-19) Market Size by Type
- 10.2.1 Asia Vaccine (Include COVID-19) Market Size by Type (2021-2026)
- 10.2.2 Asia Vaccine (Include COVID-19) Market Size by Type (2027-2032)
- 10.2.3 Asia Vaccine (Include COVID-19) Market Share by Type (2021-2032)
- 10.3 Asia Vaccine (Include COVID-19) Market Size by Application
- 10.3.1 Asia Vaccine (Include COVID-19) Market Size by Application (2021-2026)
- 10.3.2 Asia Vaccine (Include COVID-19) Market Size by Application (2027-2032)
- 10.3.3 Asia Vaccine (Include COVID-19) Market Share by Application (2021-2032)
- 10.4 Asia Vaccine (Include COVID-19) Market Size by Country
- 10.4.1 Asia Vaccine (Include COVID-19) Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Vaccine (Include COVID-19) Market Size by Country (2021-2026)
- 10.4.3 Asia Vaccine (Include COVID-19) Market Size by Country (2027-2032)
- 10.4.4 Asia Vaccine (Include COVID-19) Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Vaccine (Include COVID-19) Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Vaccine (Include COVID-19) Market Size by Type
- 11.2.1 South America, Middle East & Africa Vaccine (Include COVID-19) Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Vaccine (Include COVID-19) Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Vaccine (Include COVID-19) Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Vaccine (Include COVID-19) Market Size by Application
- 11.3.1 South America, Middle East & Africa Vaccine (Include COVID-19) Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Vaccine (Include COVID-19) Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Vaccine (Include COVID-19) Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Vaccine (Include COVID-19) Market Size by Country
- 11.4.1 South America, Middle East & Africa Vaccine (Include COVID-19) Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Vaccine (Include COVID-19) Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Vaccine (Include COVID-19) Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Vaccine (Include COVID-19) Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst